title: Comparison of Mizoribine and Mycophenolate Mofetil With a Tacrolimus-Based Immunosuppressive Regimen in Living-Donor Kidney Transplantation Recipients: A Retrospective Study in China.
abstract: BACKGROUND
  A retrospective study was conducted to investigate the prevalence of gastrointestinal (GI) symptoms as well as the efficacy and safety of mizoribine (MZR) and mycophenolate mofetil (MMF) in Chinese living-donor kidney transplantation (LDKT).
  
  
  METHODS
  Forty-two recipients enrolled between January 2012 and March 2014 were treated with either MZR (n = 22) or MMF (n = 20). All patients were treated in combination with a tacrolimus-based immunosuppressive regimen, besides the study drugs.
  
  
  RESULTS
  GI symptoms were observed in 1 of 22 patients (4.5%) and 10 of 20 patients (50%) in MZR treatment group and MMF treatment group, respectively (P = .001), during the post-transplantation 1 year. No significant differences in the incidence of acid reflux, bloated stomach feeling, and constipation were observed between the two groups. No recipient developed diarrhea in the MZR treatment group, whereas 30% of the MMF treatment group developed diarrhea (P = .007). The averages of GI symptom severity total score and diarrhea score were significantly lower in the MZR treatment group compare with MMF treatment group. There were no inter-group differences in background characteristics. There were no significant differences in acute rejection rate and clinical findings between these two groups, whereas the prevalence of cytomegalovirus infection and leukopenia were significantly lower in the MZR treatment group. There was no significant difference on adverse events such as hyperuricemia or other adverse events.
  
  
  CONCLUSIONS
  This study demonstrated a significantly lower incidence of GI symptoms for treatment with MZR compared with MMF and good efficacy and safety in Chinese LDKT with MZR.
authors.affiliation: Institute of Liver Transplantation, General Hospital of Chinese People's Armed Police Force, Beijing, China; Organ Transplantation Center, Tianjin First Center Hospital, Tianjin, China. Electronic address: shiyi_2016@126.com.
authors.forename: Y
authors.initials: Y
authors.lastname: Shi
authors.affiliation: Institute of Liver Transplantation, General Hospital of Chinese People's Armed Police Force, Beijing, China.
authors.forename: H
authors.initials: H
authors.lastname: Liu
authors.affiliation: Institute of Liver Transplantation, General Hospital of Chinese People's Armed Police Force, Beijing, China.
authors.forename: X-G
authors.initials: XG
authors.lastname: Chen
authors.affiliation: Institute of Liver Transplantation, General Hospital of Chinese People's Armed Police Force, Beijing, China; Organ Transplantation Center, Tianjin First Center Hospital, Tianjin, China.
authors.forename: Z-Y
authors.initials: ZY
authors.lastname: Shen
mesh_terms: D000328:Adult; D002681:China; D003586:Cytomegalovirus Infections / Q000139:chemically induced; D004359:Drug Therapy, Combination; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D016030:Kidney Transplantation / Q000379:methods*; D007970:Leukopenia / Q000139:chemically induced; D019520:Living Donors; D008297:Male; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000009:adverse effects*; D011184:Postoperative Period; D012189:Retrospective Studies; D012263:Ribonucleosides / Q000009:adverse effects*; D016559:Tacrolimus / Q000009:adverse effects*; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D012263:Ribonucleosides; C010052:mizoribine; D009173:Mycophenolic Acid; D016559:Tacrolimus